Ensign Peak Advisors Inc Has $7.16 Million Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Ensign Peak Advisors Inc cut its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 23.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 114,786 shares of the company's stock after selling 34,313 shares during the period. Ensign Peak Advisors Inc owned about 0.34% of TransMedics Group worth $7,157,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of TMDX. Atlas Capital Advisors Inc. acquired a new position in shares of TransMedics Group during the fourth quarter worth $31,000. Hager Investment Management Services LLC acquired a new position in shares of TransMedics Group during the fourth quarter worth $33,000. Sachetta LLC acquired a new position in shares of TransMedics Group during the fourth quarter worth $40,000. AlphaQuest LLC acquired a new position in shares of TransMedics Group during the fourth quarter worth $52,000. Finally, Arcadia Investment Management Corp MI acquired a new position in shares of TransMedics Group during the fourth quarter worth $72,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Trading Down 0.2%

TMDX traded down $0.23 during trading on Friday, reaching $121.58. 966,002 shares of the stock traded hands, compared to its average volume of 1,357,894. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The stock has a market capitalization of $4.11 billion, a PE ratio of 129.34 and a beta of 1.91. The stock's 50-day moving average is $83.99 and its 200 day moving average is $75.90. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.29 by $0.41. The business had revenue of $143.54 million for the quarter, compared to analysts' expectations of $123.39 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business's quarterly revenue was up 48.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.35 earnings per share. Equities analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insider Buying and Selling at TransMedics Group

In other news, Director Edward M. Basile sold 6,000 shares of the company's stock in a transaction dated Friday, May 9th. The shares were sold at an average price of $115.63, for a total transaction of $693,780.00. Following the transaction, the director now owns 732 shares in the company, valued at approximately $84,641.16. This represents a 89.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 7.00% of the company's stock.

Wall Street Analysts Forecast Growth

TMDX has been the subject of several research analyst reports. Canaccord Genuity Group reiterated a "buy" rating and set a $104.00 price target on shares of TransMedics Group in a report on Tuesday, March 11th. Piper Sandler reiterated an "overweight" rating and set a $125.00 price target (up from $105.00) on shares of TransMedics Group in a report on Friday, May 9th. Oppenheimer boosted their price objective on shares of TransMedics Group from $125.00 to $130.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. Finally, Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research note on Wednesday, April 23rd. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $126.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.